Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04008004 · ClinicalTrials.gov registry record · Phase 1
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT04008004 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 99 participants.
The verdict
NCT04008004, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-514 in healthy adult subjects. Part 2 is randomized, double -blind, placebo-controlled study including subjects with Hepatitis B Virus. It will assess the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days of orally administered doses of EDP-514 in nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection
Interventions
- DRUG Placebo
- DRUG EDP-514
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2021-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04008004
The ClinicalTrials.gov registry entry for NCT04008004 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04008004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04008004 about?
NCT04008004 is a clinical study titled "A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)". Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-514 in healthy adult subjects. Part 2 is randomized, double -blind, placebo-controlled study including subjects with ...
What is the current status of trial NCT04008004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2019-06-26. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT04008004?
The interventions under investigation include: Placebo (DRUG), EDP-514 (DRUG).
Who is sponsoring clinical trial NCT04008004?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.